Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Hypersensitivity and allergy

New drug could reduce symptoms of gluten exposure in people with coeliac disease

Research into a drug to reduce symptoms of inadvertent gluten exposure in people with coeliac disease has shown promising results.

Micrograph of the jejunum affected by coeliac disease

Source: Biophoto Associates / Science Photo Library

Researchers randomly assigned patients on a gluten-free diet to six injections of a monoclonal antibody, called AMG 714, over a ten-week period and found significant reductions in intestinal inflammation

A monoclonal antibody could help reduce symptoms of coeliac disease in people with the condition who are accidentally exposed to gluten, according to study findings presented at Digestive Disease Week, held in Washington DC on 2–5 June 2018[1].

Researchers randomly assigned patients on a gluten-free diet to six injections of the drug, known as AMG 714, at a dose of either 150mg or 300mg, or a placebo over a ten-week period. From week 2 to 2 weeks after treatment (week 12), the patients then underwent a gluten exposure challenge.

While there was no significant difference in the primary end point — a measurement of damage to the villous lining of the intestine — between treatment groups, there were significant reductions in inflammation and symptoms in response to gluten consumption.

Patients receiving the highest dose of AMG 714 had no clinically active disease at week 12 and also had a significant improvement in self-reported outcomes, compared with placebo.

The researchers said there was a need for treatments for coeliac disease, as even on a gluten-free diet people are often inadvertently exposed to gluten.

“AMG 714 merits development as an adjunct to [gluten-free diet] in non-responsive coeliac disease,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205174

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Micrograph of the jejunum affected by coeliac disease

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.